Enveda just put another $311 million behind its bet that AI can uncover medicines hidden in nature.
The Boulder, Colorado-based biotechnology company closed a $311 million Series E round led by Catalio Capital Management, doubling its valuation from a year ago to about $2 billion.
The round also drew new backing from Durable Capital Partners, ICONIQ, Lightspeed, Surveyor Capital, accounts advised by T. Rowe Price Investment Management, Digitalis Ventures, a sovereign wealth fund, and Alderline Group. Existing investors including Baillie Gifford, Premji Invest, Lux Capital and others also participated.
The financing takes Enveda’s total capital raised since its 2019 founding to more than $845 million, the company said.
Enveda’s core technology is PRISM, an AI platform designed to find potentially useful molecules in plants, microbes, and other living systems. Instead of designing compounds from scratch, the system uses mass spectrometry data to predict molecular structures, guide laboratory experiments, and rank compounds by potential therapeutic value.
That approach has generated 17 development candidates since 2019, three of which have reached human trials. Two produced early clinical results this year. ENV-294, an oral treatment being studied for atopic dermatitis and asthma, reduced eczema severity by an average of 85% after 42 days in a Phase 1b study, Enveda said.
ENV-308, meanwhile, is being developed to help people maintain weight loss after stopping GLP-1 medicines and was well tolerated in a study involving 88 healthy volunteers. A third drug, ENV-6946, is in Phase 1 testing for inflammatory bowel disease.
Where the money goes
The new funding will push ENV-294 and ENV-308 into later-stage trials and additional indications, while ENV-6946 advances through mid-stage development. Enveda also plans to advance additional candidates into clinical trials for inflammatory and metabolic conditions and expand the automated laboratory that supports PRISM.
That matters because discovery is only one part of drug development. Enveda now has to show that compounds identified through its AI-and-natural-product approach can consistently produce meaningful results in patients.
The bigger bet behind the round
The new funding moves Enveda into a more consequential part of drug development. Early discovery can show that an AI system is capable of finding promising molecules, but advancing those molecules through increasingly demanding human trials is where the company’s technology and business model will face a much tougher test.
That makes the next phase important for more than Enveda’s valuation. If its candidates continue producing positive results, the company will have stronger evidence that combining AI with nature-derived chemistry can generate a repeatable pipeline rather than isolated discoveries.
Enveda CEO Viswa Colluru said the company believes AI can help address the difficulty of finding promising molecules in the first place.
“The industry has gotten really, really good at commercializing a molecule once you know it’s right, but has increasingly gotten worse at finding the right molecule,” Colluru told The Wall Street Journal.
Specialized AI creates new infrastructure demands
Enveda’s expansion shows how AI spending is moving into specialized industries that require more than access to a large language model.
AI drug discovery depends on compute, scientific data pipelines, laboratory automation and infrastructure connecting models with physical experiments. As Enveda expands the automated laboratory supporting PRISM, those technology requirements could grow alongside its drug pipeline.
For cloud providers, infrastructure vendors, systems integrators and technology service providers, companies like Enveda represent a growing class of AI customers with specialized needs. The opportunity centers on supplying the compute, data infrastructure, security and integration behind increasingly automated research environments.
Enveda still has to prove its AI-discovered drugs can succeed in larger clinical trials. But its $311 million raise shows investors are willing to fund the costly transition from AI-assisted discovery to real-world drug development.
Want to learn more AI tips, tricks, and prompting techniques? Channel Insider readers get free 7-day access to The Neuron Academy, our practical learning platform designed to help professionals use AI more confidently at work. Browse all lessons →